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Objective 
1. Discuss the clinical impact of pharmacist interventions in implementing 
prescribing criteria for calcitonin at Baptist Hospital of Miami 
Hypercalcemia
Classifications of hypercalcemia: 
Mild= Corrected serum 
calcium < 12 mg/dL 
Moderate= Corrected 
serum calcium 12-14 mg/dL
Severe= Corrected serum 
calcium >14 mg/dL 
Clinical condition defined as serum calcium levels exceeding the upper 
limit of normal (10.5 mg/dL).
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
Regulation of Calcium in the Plasma 
 Parathyroid Hormone (PTH) Increases serum calcium levels 
 Stimulates production of vitamin D within the kidney 
 Facilitates mobilization of calcium from bone 
 Maximizes tubular reabsorption of calcium within the kidney 
 1,25-dihydroxyvitamin D3 (Calcitriol)  Increases serum calcium levels 
 Facilitates absorption of calcium from the small intestine 
 Enhances reflux of calcium out of bone 
 Calcitonin Reduces serum calcium levels 
 Secreted from thyroid gland in response to an increase in calcium blood concentrations  
 Promotes renal excretion of calcium 
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
Etiology of Hypercalcemia 
Primary hyperparathyroidism Malignancy-associated hypercalcemia 
Vitamin D intoxication 
Medications 
• Thiazide diuretics 
• Lithium
• Calcium containing antacids 
Familial hypocalciuric hypercalcemia Immobilization
Hypercalcemia Treatment
Intravenous (IV) 
Hydration
Recommended for 
mild, moderate & severe 
hypercalcemia
IV Bisphosphonates
Recommended for
moderate & severe 
hypercalcemia 
Calcitonin
Reserved for 
moderate (symptomatic) & 
severe hypercalcemia
First-line therapy 
Carroll MF, Schade DS.Am Fam Physician.2003;67:1959-66.
First-line therapy 
Treatment 
Therapy Mode of Action Dose Onset of 
Action
Adverse Effects
IV fluids 
• Increases
glomerular 
filtration rate
• Enhances calcium 
excretion
200-500 mL/hr
or 2-4 L/day Immediate 
• Volume overload
• HF exacerbation
Pamidronate
Inhibits osteoclast 
activity leading to 
decrease bone 
resorption 
60-90 mg IV 
over 2-4 hours 
X 1 dose 
• ≤24 hours 
• Maximum 
effect in ≤7
days 
• Nephrotoxicity
• Flu-like symptoms 
Zoledronic 
acid
Inhibits osteoclast 
activity leading to 
decrease bone 
resorption 
4 mg IV over 15 
minutes X 1 
dose 
• ≤24 hours 
• Maximum 
effect in ≤7
days 
• Nephrotoxicity
• Flu-like symptoms 
Calcitonin 
• Inhibits osteoclast 
activity 
• Enhances calcium 
excretion
4-8 IU /kg SQ or 
IM every 12 
hours 
~2 hours 
• Rebound effect
• Vomiting 
• Cramps 
• Flushing 
Rosner M, Dalkin A.Clin J Am Soc Nephrol.2012:7;1722-1729.
Thomas SA, Chung S.Jhop.2016:6(1).
Calcitonin (Miacalcin®) 
 FDA approved indications:
 Postmenopausal osteoporosis 
 Hypercalcemia 
 Paget’s disease 
 Hypercalcemia Dosing:
 Dose: 4 units/kg IM/SQ every 12 hrs
 May increase to 8 units/kg every 12 hrs
if response is unsatisfactory 
 Concerns with overuse of 
calcitonin:
 Hypocalcemia
 Tachyphylaxis:  Hypocalcemic effect 
diminishes within 24 to 48 hours
 Price: 400 units/2 mL (200 units/mL): 
$2,712.09
Purpose 
 To assess the prescribing 
practices of calcitonin at Baptist 
Hospital of Miami (BHM) and to 
optimize the utilization of 
calcitonin in patients with 
hypercalcemia.
 The intent of this project is to 
facilitate the implementation of 
a calcitonin prescribing criteria 
through pharmacist review and 
clinical recommendations at 
BHM
Project design 
 Phase I: 
 Retrospective chart review of all patients who received calcitonin injections at Baptist 
Hospital of Miami (BHM) between October 1st, 2017-September 30th, 2019.
 Phase II: 
 Prospective review post implementation of calcitonin prescribing criteria for the 
treatment of hypercalcemia.
 Resident will be on call to determine if initiation of calcitonin meets protocol criteria and 
make recommendations to the ordering physician as needed. 
Outcomes
Primary 
Outcome 
Duration of 
calcitonin therapy 
(hrs)
Secondary 
Outcomes
Number of 
pharmacy 
interventions 
Percentage of 
patients treated 
with IV fluids and IV 
bisphosphonates 

Baseline Demographics  
Phase I (N=94) Phase II (N=16)
Mean age, years 69 68
Gender – male, n (%) 53 (56.4) 4 (25)
Mild Hypercalcemia, n (%) 13 (13.8) 7 (43.8)
Moderate Asymptomatic Hypercalcemia, n (%) 9 (9.6) 2 (12.5)
Moderate symptomatic Hypercalcemia, n (%) 31 (33) 4 (25)
Severe Hypercalcemia, n (%) 41 (43.6) 3 (18.8)
Demographics  
 Phase I:  Phase II:
88.3%
7.4%
4.3%
Indication
Hypercalcemia of Malignancy Primary Hyperparathyroidism Other
93.8%
6.2%
Indication
Hypercalcemia of Malignancy Primary Hyperparathyroidism
Demographics 
17.0%
30.9%
48.9%
3.2%
Ordering Provider Specialty
Internal Medicine Nephrology Oncology Other
 Phase II: Phase I:
12.5%
31.2%56.3%
Ordering Provider Specialty 
Internal Medicine Nephrology Oncology
Results: Primary Outcome
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p= 0.0107
≤ 24 hrs > 24 hrs
68.8% 31.2%
Results: Secondary Outcomes
 Number of pharmacy interventions = 16
 75% acceptance rate 
 Usage of first-line therapy:
Phase I 
(N=94) 
Phase II
(N=16) p-value
IV Fluids – n (%) 76 (81) 16 (100) p= 0.0689
IV Bisphosphonates – n (%) 83 (88) 16 (100) p= 0.3613
Pharmacist Interventions 
Severity of Hypercalcemia Discontinuation of Calcitonin
Shorten Duration of 
Therapy Declined
Mild (n=7) 2 3 2
Moderate Asymptomatic (n=2) 0 2 0
Moderate Symptomatic (n=4) N/A 2 2
Severe (n=3) N/A 3 0
ଵଶ ௜௡௧௘௥௩௘௡௧௜௢௡௦ ௔௖௖௘௣௧௘ௗ
ଵ଺ ௧௢௧௔௟ ௜௡௧௘௥௩௘௡௧௜௢௡௦
= 75% acceptance rate 
Results: Secondary Outcomes
 Phase II:
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Results: Secondary Outcomes
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• # of doses reduced by 45%
• # of vials saved: 18
• Calculated cost savings ~$48,000 cost savings 
• Extrapolated BHM cost savings ~ $158,000/year
 Phase II:
Discussion
 Limitations: 
 Low volume of calcitonin orders due to short duration of phase II
 Inability to accurately assess for presence of symptoms for hypercalcemia
 e.g., fatigue due to hypercalcemia vs. underlying disease 
 Lack of documentation of symptoms 
 Opportunities: 
 Educate pharmacists on optimal calcitonin use and monitoring 
 Establish prescribing criteria to facilitate utilization of calcitonin across Baptist Health-System 
 Develop electronic order-sets for the treatment of hypercalcemia based on severity level 
Conclusion
 Implementation of a calcitonin prescribing criteria through active pharmacist review 
and recommendations can facilitate the optimization of calcitonin use in patients with 
hypercalcemia at BHM and potentially lead to cost savings.   
Post-Assessment
 Which of the following classifications of hypercalcemia is calcitonin recommended 
for? 
A.  Moderate symptomatic hypercalcemia
B.  Severe hypercalcemia 
C.  Asymptomatic moderate hypercalcemia 
D.  A & B 
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